SE7910501L - Lekemedel for behandling av det centrala nervsystemet - Google Patents
Lekemedel for behandling av det centrala nervsystemetInfo
- Publication number
- SE7910501L SE7910501L SE7910501A SE7910501A SE7910501L SE 7910501 L SE7910501 L SE 7910501L SE 7910501 A SE7910501 A SE 7910501A SE 7910501 A SE7910501 A SE 7910501A SE 7910501 L SE7910501 L SE 7910501L
- Authority
- SE
- Sweden
- Prior art keywords
- treatment
- nervous system
- central nervous
- compositions
- hyperkinesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2856393A DE2856393C2 (de) | 1978-12-27 | 1978-12-27 | Arzneimittel zur Behandlung von Morbus Parkinson |
Publications (2)
Publication Number | Publication Date |
---|---|
SE7910501L true SE7910501L (sv) | 1980-06-28 |
SE448517B SE448517B (sv) | 1987-03-02 |
Family
ID=6058522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE7910501A SE448517B (sv) | 1978-12-27 | 1979-12-19 | Farmaceutiskt preparat som paverkar det centrala nervsystemet, innehallande 1,3-dimetyl-5-aminoadamantan och en metylxantinforening |
Country Status (10)
Country | Link |
---|---|
US (1) | US4273774A (sv) |
JP (1) | JPS5589219A (sv) |
BE (1) | BE880905A (sv) |
CA (1) | CA1121726A (sv) |
DE (1) | DE2856393C2 (sv) |
FR (1) | FR2445145A1 (sv) |
GB (1) | GB2044098B (sv) |
NL (1) | NL7909307A (sv) |
SE (1) | SE448517B (sv) |
SG (1) | SG3185G (sv) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE33080E (en) * | 1981-08-31 | 1989-10-03 | Exxon Research And Engineering Company | Adamantane catalyzed paraffin isomerization |
US5506231A (en) * | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
US5614560A (en) * | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
US5455279A (en) * | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
DE19707655A1 (de) * | 1997-02-26 | 1998-08-27 | Hoechst Ag | Kombinationspräparat zur Anwendung bei Demenz |
US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
JP2006506378A (ja) | 2002-10-24 | 2006-02-23 | メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン | 1−アミノシクロヘキサン誘導体及びアセチルコリンエステラーゼ阻害薬を用いる併用療法 |
KR20070104480A (ko) * | 2003-05-27 | 2007-10-25 | 포레스트 래보러토리즈, 인코포레이티드 | 우울증 및 그 밖의 기분장애의 치료를 위한 nmda수용체 길항제 및 선택적 세로토닌 재흡수 억제제의 배합물 |
MXPA05012810A (es) * | 2003-06-16 | 2006-02-13 | Allergan Inc | Formas de dosis oral de memantina. |
AU2004316119B2 (en) * | 2003-10-22 | 2008-04-24 | Merz Pharma Gmbh & Co. Kgaa | The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic AB peptides in amyloidopathies |
AR046314A1 (es) | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | Composiciones que comprenden ciclohexilaminas y aminoadamantanos |
CA2551689A1 (en) * | 2004-01-05 | 2005-07-28 | Merz Pharma Gmbh & Co. Kgaa | Memantine for the treatment of mild and mild-to-moderate alzheimer's disease |
US7456224B2 (en) * | 2004-04-05 | 2008-11-25 | Forest Laboratories Holdings, Ltd. | Method for treating autism |
MXPA06014587A (es) * | 2004-06-17 | 2007-04-27 | Forest Laboratories | Formulaciones de liberacion modificada de formulaciones de dosificacion oral de memantina. |
US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
AU2005328701B2 (en) | 2004-06-17 | 2009-08-13 | Merz Pharma Gmbh & Co. Kgaa | Drinkable immediate release tablet made with direct compression of memantine or neramexane |
TW200616608A (en) * | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
BRPI0515560A (pt) * | 2004-09-23 | 2008-07-29 | Merz Pharma Gmbh & Co Kgaa | memantina para o tratamento de distúrbios comportamentais infantis |
US8058291B2 (en) * | 2005-04-06 | 2011-11-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of CNS-related conditions |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
US20060205822A1 (en) * | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
EP1898890A1 (en) * | 2005-06-16 | 2008-03-19 | Forest Laboratories, Inc. | Modified and immediate release memantine bead formulation |
US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
US20080008743A1 (en) * | 2006-07-06 | 2008-01-10 | Forest Laboratories Holdings Limited | Orally Dissolving Formulations of Memantine |
ATE488520T1 (de) | 2006-08-04 | 2010-12-15 | Merz Pharma Gmbh & Co Kgaa | Pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin |
WO2008063847A2 (en) * | 2006-11-03 | 2008-05-29 | Forest Laboratories Holdings Limited | Method for treating autism |
EP2085398A1 (en) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
WO2009151498A2 (en) * | 2008-03-28 | 2009-12-17 | Forest Laboratories Holdings Limited | Memantine formulations |
EP2288345B1 (en) | 2008-04-18 | 2015-06-10 | University College Dublin National University Of Ireland, Dublin | Psycho-pharmaceuticals |
EP2111858A1 (en) | 2008-04-25 | 2009-10-28 | EPFL Ecole Polytechnique Fédérale de Lausanne | Novel treatment for alzheimer's disease |
US20090275597A1 (en) * | 2008-05-02 | 2009-11-05 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
EP2138173A1 (en) | 2008-06-26 | 2009-12-30 | Merz Pharma GmbH & Co.KGaA | Pharmaceutical compositions comprising aminoadamantane derivatives |
TW201116532A (en) | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
MX365650B (es) | 2009-12-02 | 2019-06-10 | Adamas Pharmaceuticals Inc | Composiciones de amantadina y metodos para su uso. |
US20110251239A1 (en) | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
WO2012052451A1 (en) | 2010-10-18 | 2012-04-26 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
CN103282349A (zh) | 2010-10-29 | 2013-09-04 | 德国麦氏大药厂 | 吲哚衍生物及其制备方法 |
JP5916746B2 (ja) | 2010-11-15 | 2016-05-11 | エージンバイオ, インコーポレイテッド | 認知障害を処置するためのピリダジン誘導体、組成物、および方法 |
AR084515A1 (es) | 2010-12-22 | 2013-05-22 | Merz Pharma Gmbh & Co Kgaa | Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras |
WO2012085166A1 (en) | 2010-12-22 | 2012-06-28 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
WO2012152854A1 (en) | 2011-05-12 | 2012-11-15 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
WO2012172093A1 (en) | 2011-06-17 | 2012-12-20 | Merz Pharma Gmbh & Co. Kgaa | Dihydroindolizine derivate as metabotropic glutamate receptor modulators |
EP2650284A1 (en) | 2012-04-10 | 2013-10-16 | Merz Pharma GmbH & Co. KGaA | Heterocyclic derivatives as metabotropic glutamate receptor modulators |
RU2488388C1 (ru) | 2012-05-24 | 2013-07-27 | Ооо "Валента Интеллект" | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
PL2892540T3 (pl) * | 2012-09-06 | 2018-12-31 | Mcpharma Biotech Inc. | Leczenie biegunki i biegunki po odsadzeniu przy pomocy opornej skrobi ziemniaczanej |
WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
CN106068256B (zh) | 2013-12-20 | 2020-10-23 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法 |
JP6604957B2 (ja) | 2014-02-04 | 2019-11-13 | フォレスト・ラボラトリーズ・ホールディングス・リミテッド | ドネペジル組成物及びアルツハイマー病を治療する方法 |
CN113264939A (zh) | 2015-06-19 | 2021-08-17 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
CN109922796B (zh) | 2016-06-23 | 2023-04-07 | 考里安有限责任公司 | 具有亲水和疏水域的粘合剂基质和治疗剂 |
EP3490541A2 (en) | 2016-07-27 | 2019-06-05 | Corium International, Inc. | Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs byin situ |
KR102424270B1 (ko) | 2016-07-27 | 2022-07-25 | 코리움, 인크. | 경구 전달과 생물학적으로 동등한 약물동역학을 가진 경피 전달 시스템 |
RU2764764C2 (ru) | 2016-07-27 | 2022-01-21 | Кориум Интернэшнл, Инк. | Трансдермальные системы доставки мемантина |
US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio Inc | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
US10369187B2 (en) | 2017-02-09 | 2019-08-06 | Vanderbilt University | Peptide regulators of JNK family kinases |
WO2019126531A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
CN112601749B (zh) | 2018-06-19 | 2024-03-26 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物,组合物和方法 |
WO2023154014A1 (en) | 2022-02-08 | 2023-08-17 | Sahin Fikret | Nmdar antagonists prevent ageing and aging-associated conditions and diseases through increasing 20s proteasome activity |
US20240132513A1 (en) | 2022-08-19 | 2024-04-25 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3864489A (en) * | 1972-03-20 | 1975-02-04 | Gen Foods Corp | Treatment of hyperkinetic conditions with caffeine |
NL7305644A (sv) * | 1972-04-20 | 1973-10-23 | ||
AU6889274A (en) * | 1973-05-17 | 1975-11-20 | Astra Laekemedel Ab | Treatment of neurological disorders |
DE2518677A1 (de) * | 1974-05-06 | 1975-11-20 | Sandoz Ag | Neue pharmazeutische zubereitungen |
-
1978
- 1978-12-27 DE DE2856393A patent/DE2856393C2/de not_active Expired
-
1979
- 1979-12-19 US US06/105,419 patent/US4273774A/en not_active Expired - Lifetime
- 1979-12-19 SE SE7910501A patent/SE448517B/sv not_active IP Right Cessation
- 1979-12-24 CA CA000342584A patent/CA1121726A/en not_active Expired
- 1979-12-24 NL NL7909307A patent/NL7909307A/nl not_active Application Discontinuation
- 1979-12-26 FR FR7931664A patent/FR2445145A1/fr active Granted
- 1979-12-27 BE BE0/198784A patent/BE880905A/fr not_active IP Right Cessation
- 1979-12-27 JP JP16955179A patent/JPS5589219A/ja active Pending
- 1979-12-28 GB GB7944464A patent/GB2044098B/en not_active Expired
-
1985
- 1985-01-11 SG SG31/85A patent/SG3185G/en unknown
Also Published As
Publication number | Publication date |
---|---|
FR2445145B1 (sv) | 1984-10-26 |
US4273774A (en) | 1981-06-16 |
BE880905A (fr) | 1980-06-27 |
SG3185G (en) | 1985-06-14 |
GB2044098A (en) | 1980-10-15 |
SE448517B (sv) | 1987-03-02 |
GB2044098B (en) | 1983-01-26 |
JPS5589219A (en) | 1980-07-05 |
DE2856393A1 (de) | 1980-07-03 |
NL7909307A (nl) | 1980-07-01 |
CA1121726A (en) | 1982-04-13 |
DE2856393C2 (de) | 1983-04-28 |
FR2445145A1 (fr) | 1980-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE7910501L (sv) | Lekemedel for behandling av det centrala nervsystemet | |
ES2193391T3 (es) | Antagonistas muscarinicos. | |
BR9407910A (pt) | Composto composiçao farmacêutica uso do composto processo de tratamento de distúrbios no sistema nervoso central e processo de preparaçao do composto | |
ATE76747T1 (de) | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. | |
AU637086B2 (en) | Use of 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutically acceptable salts in the preparation of pharmaceutical compositions in controlled- release form active in the therapy of organic mental disturbances, and the relative pharmaceutical compositions | |
ATE73331T1 (de) | Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. | |
ES2096312T3 (es) | Derivado de quinuclidina como antagonista de la sustancia p. | |
ES8603870A1 (es) | Un procedimiento para la preparacion de derivados de 2,2'-iminobisetanol. | |
FI954130A (sv) | Heterocykliska föreningar och deras framställning och användning | |
DK599789A (da) | 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler | |
BR9807950A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto | |
ATE223399T1 (de) | Quinazolin-4-on ampa antagonisten | |
NO307464B1 (no) | Galantaminderivater, farmasøytisk sammensetning inneholdende samme samt deres anvendelse for fremstilling av medikamenter | |
TNSN90021A1 (fr) | Procede de preparation de tetrahydroimidazo (1,4) benzodiazepin -2- thiones antivirales | |
BRPI0409878A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
HU9802897D0 (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient | |
FR2434804A1 (fr) | Derives de la n-phenyl-indoline, leur preparation et leur application comme medicaments | |
DE10299023I1 (de) | Antineoplastisch wirkender und den Antineoplastischen effekt Verstaerkender Wirkstoff | |
MX9300205A (es) | Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene. | |
ATE110714T1 (de) | Derivate von hydroxaminsäure die lipoxygenase hemmen. | |
ZA894048B (en) | New condensed diazepinones,processes for preparing them and pharmaceutical compositions containing these compounds | |
BR0308293A (pt) | Terapia à base de estatina para aumentar a manutenção cognitiva | |
US20070141167A1 (en) | Use of Benzyl Nicotinate for Pain Relief | |
BR9808546A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições do ser humano, tratar ou reduzir o risco de doença inflamatória e o risco da dor em uma pessoa que sofre, ou em risco, da dita doença e para a preparação do composto | |
ES2184285T3 (es) | Compuestos farmaceuticos que contienen diclorhidrato de cinconina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NUG | Patent has lapsed |
Ref document number: 7910501-1 Effective date: 19920704 Format of ref document f/p: F |